Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21027IB" target="_blank" >RIV/61988987:17110/20:A21027IB - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00116111 RIV/00216208:11110/20:10412894 RIV/00216208:11150/20:10412894 RIV/65269705:_____/20:00072869 and 4 more
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16572" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16572</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.16572" target="_blank" >10.1111/bjh.16572</a>
Alternative languages
Result language
angličtina
Original language name
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model
Original language description
Smouldering multiple myeloma (SMM) presents without MM defining symptoms. We aimed to identify patients with SMM with an 80% risk of progression within 2 years using only serum parameters. In total, 527 patients with SMM were included and divided into a training group (287 patients from the Czech Myeloma Group [CMG]) and an independent validation group (240 patients from Heidelberg). The median follow-up was 2 center dot 4 and 2 center dot 5 years, respectively. Progression to MM occurred in 51 center dot 9% of the CMG and 38 center dot 8% of the Heidelberg patients, respectively. The median risk of progression was 11 center dot 0% (CMG) and 9 center dot 7% (Heidelberg) per year, during the 5 years after diagnosis. A serum involved/uninvolved free light-chain ratio of >30, immunoparesis, and serum monoclonal (M) protein of >= 2 center dot 3 g/dl emerged as powerful predictors of 2-year progression rate with a hazard ratio (HR) of 2 center dot 49 (95% confidence interval [CI] 1 center dot 49-4 center dot 17), HR of 2 center dot 01 (95% CI 1 center dot 36-2 center dot 96) and HR of 2 center dot 00 (95% CI 1 center dot 44-2 center dot 79) (P < 0 center dot 001) in univariate Cox regression analysis, respectively. Based on this, the CMG model identified patients with SMM with a 2-year risk of progression of 78 center dot 7% (95% CI 53 center dot 1-95 center dot 7; HR 6 center dot 8;P < 0 center dot 001, CMG) and 81 center dot 3% (95% CI 47 center dot 1-98 center dot 8; HR 38 center dot 63;P < 0 center dot 001, Heidelberg). Serum parameters in the CMG model allow identification of patients with SMM with an 80% risk of progression to symptomatic MM within 2 years.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV18-03-00203" target="_blank" >NV18-03-00203: Liquid biopsies in plasma cell leukemia</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
—
Volume of the periodical
190
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
189-197
UT code for WoS article
000549486800038
EID of the result in the Scopus database
—